Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15460MR)

This product GTTS-WQ15460MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15460MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6711MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ8114MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ9032MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ1776MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ2924MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ14196MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ14532MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ381MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW